-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
5 Value Stocks In The Healthcare Sector
5 Value Stocks In The Healthcare Sector
What are Value Stocks?
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:
- Cullinan Oncology (NASDAQ:CGEM) - P/E: 4.94
- ProPhase Labs (NASDAQ:PRPH) - P/E: 5.17
- ITeos Therapeutics (NASDAQ:ITOS) - P/E: 2.64
- Procaps Gr (NASDAQ:PROC) - P/E: 7.77
- Kiniksa Pharmaceuticals (NASDAQ:KNSA) - P/E: 7.78
Cullinan Oncology saw a decrease in earnings per share from 3.77 in Q2 to $-0.54 now. ProPhase Labs saw a decrease in earnings per share from 0.4 in Q2 to $0.06 now. ITeos Therapeutics's earnings per share for Q3 sits at $0.03, whereas in Q2, they were at 0.15. Procaps Gr's earnings per share for Q3 sits at $0.22, whereas in Q2, they were at -0.07. Kiniksa Pharmaceuticals has reported Q3 earnings per share at $3.18, which has increased by 1196.55% compared to Q2, which was -0.29.
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.
What are Value Stocks?
什么是价值股?
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
传统上,与同行业公司的股票价格相比,价值股票的价格较低。这表明该公司的估值可能被低估了,因为投资者对此类公司的兴趣不大。最常用的价值检查方法是市盈倍数或市盈率。低市盈倍数很好地表明股票被低估了。
Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching:
Benzinga Insights编制了一份可能值得关注的医疗保健行业价值股清单:
- Cullinan Oncology (NASDAQ:CGEM) - P/E: 4.94
- ProPhase Labs (NASDAQ:PRPH) - P/E: 5.17
- ITeos Therapeutics (NASDAQ:ITOS) - P/E: 2.64
- Procaps Gr (NASDAQ:PROC) - P/E: 7.77
- Kiniksa Pharmaceuticals (NASDAQ:KNSA) - P/E: 7.78
- 库里南肿瘤学 (纳斯达克股票代码:CGEM)-市盈率:4.94
- ProPhase 实验 (纳斯达克股票代码:PRPH)-市盈率:5.17
- iTeos Therap (纳斯达克股票代码:ITOS)-市盈率:2.64
- Procaps Gr (纳斯达克股票代码:PROC)-市盈率:7.77
- Kiniksa 制药 (纳斯达克股票代码:KNSA)-市盈率:7.78
Cullinan Oncology saw a decrease in earnings per share from 3.77 in Q2 to $-0.54 now. ProPhase Labs saw a decrease in earnings per share from 0.4 in Q2 to $0.06 now. ITeos Therapeutics's earnings per share for Q3 sits at $0.03, whereas in Q2, they were at 0.15. Procaps Gr's earnings per share for Q3 sits at $0.22, whereas in Q2, they were at -0.07. Kiniksa Pharmaceuticals has reported Q3 earnings per share at $3.18, which has increased by 1196.55% compared to Q2, which was -0.29.
Cullinan Oncology的每股收益从第二季度的3.77美元下降到现在的-0.54美元。ProPhase Labs的每股收益从第二季度的0.4美元下降到现在的0.06美元。iTeos Therapeutics第三季度的每股收益为0.03美元,而在第二季度,为0.15美元。Procaps Gr第三季度的每股收益为0.22美元,而在第二季度,为-0.07。Kiniksa Pharmicals公布的第三季度每股收益为3.18美元,与第二季度-0.29相比增长了1196.55%。
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.
这5只价值股票是由以下人士选出的 奔辛加洞察 基于量化分析。虽然这种有条不紊的判断过程并不旨在做出最终决定,但我们的技术可以让投资者对该行业有更多的看法。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧